Freemantle N, Anderson I M, Young P
Medicines Evaluation Group, Centre for Health Economics, University of York, Heslington, York YO10 5DD, UK.
Br J Psychiatry. 2000 Oct;177:292-302. doi: 10.1192/bjp.177.4.292.
There is uncertainty about the contribution of specific pharmacological properties to the efficacy of antidepressants.
To assess whether specific pharmacological characteristics of alternative antidepressants resulted in altered efficacy compared to that of selective serotonin reuptake inhibitors in the treatment of major depression.
Meta-regression analysis of randomised trials that compare treatment with a selective serotonin reuptake inhibitor and an alternative antidepressant.
One-hundred-and-five randomised trials were included. None of the factors identified a priori predicted a statistically significant improvement in outcome across the trials.
This analysis does not provide evidence that antidepressants acting at more than one pharmacological site differ in efficacy from drugs selective for serotonin reuptake in the treatment of major depression.
特定药理特性对抗抑郁药疗效的贡献尚不确定。
评估在治疗重度抑郁症时,与选择性5-羟色胺再摄取抑制剂相比,新型抗抑郁药的特定药理特性是否会导致疗效改变。
对比较选择性5-羟色胺再摄取抑制剂与新型抗抑郁药治疗效果的随机试验进行Meta回归分析。
纳入105项随机试验。预先确定的因素均未预测出在所有试验中结局有统计学显著改善。
该分析未提供证据表明,作用于多个药理位点的抗抑郁药在治疗重度抑郁症时,其疗效与选择性5-羟色胺再摄取药物存在差异。